Merck & Co.’s Keytruda combined with Moderna’s individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) demonstrated a 49% reduction in risk of recurrence or death at five years versus Keytruda alone in the Phase 2b KEYNOTE-942/mRNA-4157-P201 adjuvant trial for stage III/IV melanoma. This pre-planned analysis builds on earlier two- and three-year results, confirming sustained improvement in the study’s primary endpoint of recurrence-free survival (RFS). The safety profile remains consistent with prior reports, showing no new signals of severe adverse events. Merck and Moderna plan to present additional data on secondary efficacy endpoints at an upcoming oncology conference. Concurrently, the fully enrolled INTerpath-001 Phase 3 trial in adjuvant melanoma and two Phase 3 studies in non–small cell lung cancer are progressing, while multiple Phase 2 studies in renal cell carcinoma, bladder cancer and metastatic indications continue to enroll patients.

Merck faces mounting pressure heading into its fourth-quarter earnings report as Gardasil vaccine sales in China and Japan have plunged, with units sold down roughly 30% year-over-year in China and down double digits in Japan. These declines follow intensified regulatory scrutiny and heightened competition from domestic vaccine manufacturers. Market analysts warn that this erosion in a key growth driver could offset gains from immuno-oncology and hospital acute care franchises. Management commentary on pricing dynamics, volume recovery strategies and inventory destocking in these markets will be critical for investors assessing Merck’s full-year guidance and 2025 revenue trajectory.